Medicine company – Diazon http://diazon.net/ Thu, 29 Sep 2022 09:43:25 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://diazon.net/wp-content/uploads/2021/11/icon-120x120.jpg Medicine company – Diazon http://diazon.net/ 32 32 Zoetis receives backing for acquisition of veterinary drug company Jurox https://diazon.net/zoetis-receives-backing-for-acquisition-of-veterinary-drug-company-jurox/ Thu, 29 Sep 2022 07:05:11 +0000 https://diazon.net/zoetis-receives-backing-for-acquisition-of-veterinary-drug-company-jurox/ Animal health company Zoetis has received support from the ACCC for the acquisition of Australian veterinary medicine company Jurox. After accepting Zoetis’ legal undertaking to divest Jurox’s range of products, consisting of antibiotics for dry and suckler cows and teat glues for cows, the ACCC decided not to oppose the takeover. Zoetis and Jurox develop, […]]]>

Animal health company Zoetis has received support from the ACCC for the acquisition of Australian veterinary medicine company Jurox.

After accepting Zoetis’ legal undertaking to divest Jurox’s range of products, consisting of antibiotics for dry and suckler cows and teat glues for cows, the ACCC decided not to oppose the takeover.

Zoetis and Jurox develop, manufacture and sell animal health products. They are two of Australia’s leading suppliers of teat sealants and antibiotics for lactating and dry cows, which are products used to treat or prevent bacterial infections.

“Zoetis is a leader in the supply of intramammary products and Jurox is a well-known competitor with a full range of established products,” the ACCC commissioner said. Lisa Carver said.

“Without the divestiture, the proposed acquisition would combine the two largest suppliers of intramammary antibiotics for lactating cows, two of the four largest suppliers of intramammary antibiotics for dry cows and two of the three largest suppliers of teat sealants. , which would likely result in higher prices for these products.”

The ACCC’s investigation revealed that there are few alternative providers in these markets and that barriers to entry or expansion are high. This is mainly due to lengthy regulatory approval processes, high manufacturing costs and the relatively small size of the Australian market, which makes it difficult to achieve economies of scale.

To address the ACCC’s concerns, Zoetis has offered the ACCC a commitment to sell Jurox’s line of intramammary products, namely Ampiclox LC and DC, Juraclox LA, Maxalac LC and DC and U-Seal.

“The ACCC is satisfied that the divestiture commitment resolves the competition concerns raised and ensures that Jurox’s intramammary product line will continue to compete with Zoetis’ products,” said Ms. Carver.

Zoetis proposed veterinary pharmaceutical company AVet as the initial purchaser of the intramammary product line after an agreement was reached between AVet and Zoetis. The ACCC has approved AVet as the buyer.

Source: ACCC


Source link

]]>
Digital medicine company Akili completes merger with Palihapitiya SPAC https://diazon.net/digital-medicine-company-akili-completes-merger-with-palihapitiya-spac/ Mon, 22 Aug 2022 07:00:00 +0000 https://diazon.net/digital-medicine-company-akili-completes-merger-with-palihapitiya-spac/ Subscribe to our free newsletter Stay informed with the latest daily news from PSPC. X Source link]]>

Subscribe to our free newsletter

Stay informed with the latest daily news from PSPC.





















Source link

]]>
Digital medicine company Akili gets a cold reception in the market after a blank check merger https://diazon.net/digital-medicine-company-akili-gets-a-cold-reception-in-the-market-after-a-blank-check-merger/ Mon, 22 Aug 2022 07:00:00 +0000 https://diazon.net/digital-medicine-company-akili-gets-a-cold-reception-in-the-market-after-a-blank-check-merger/ Shares of Akili Interactive plunged on Monday and again on Tuesday after the digital therapies developer went public via a merger with a special-purpose acquisition company. The deal netted Akili more than $163 million, which she plans to use to commercialize her video game-based treatment for pediatric ADHD, the company said August 19. Shares of […]]]>

Shares of Akili Interactive plunged on Monday and again on Tuesday after the digital therapies developer went public via a merger with a special-purpose acquisition company. The deal netted Akili more than $163 million, which she plans to use to commercialize her video game-based treatment for pediatric ADHD, the company said August 19.

Shares of Akili opened as high as $36 on Monday, before falling below $6 by mid-Tuesday morning. The Boston-based company is now valued at less than $200 million.

Nonetheless, Akili expects the new funds, combined with his cash on hand, to provide enough money to cover at least 24 months of operations. Other digital health companies, such as Pear Therapeutics, have trimmed staff as they seek to expand their track in tougher market conditions.

Akili merged with Social Capital Suvretta Holdings Corp. I, one of many special purpose acquisition companies created by Chamath Palihapitiya, a venture capitalist and former Facebook executive who is sometimes known as “SPAC King”. Shareholders of the so-called blank check company approved the deal at a meeting on August 18.

SPAC mergers offer private companies an alternative way to jump into the public markets, allowing them to bypass a lengthy process of courting investors. But the deals have fallen out of favor recently, even as the market for traditional IPOs has cooled considerably.

Traditional IPOs have to date raised around $5 billion so far in 2022, a sharp drop from the typical $30 billion in previous years and well below the more than $100 billion raised so far. stadium in 2021, according to Dealogic data cited by the Wall Street Journal.

The pain is particularly acute in the biotech sector, which produced nearly 200 IPOs in 2020 and 2021. To date, only 15 biotech startups have gone public via IPO this year, according to data from BioPharma Dive.

Eddie Martucci, founder and CEO of Akili, will continue to lead the company, while Palihapitiya will chair its board of directors.

Akili currently has a product, a video game called EndeavorRx that is intended to improve attention function in children with ADHD. The company received Food and Drug Administration clearance in 2020 and expects a full US launch in the fourth quarter of this year.

Akili plans to use a portion of the proceeds from the deal for marketing efforts, as well as developing other digital therapies for autism spectrum disorders, multiple sclerosis and major depressive disorder.

The company’s revenue has declined in recent years as it earns less from licensing deals and has yet to complete the commercial launch of EndeavorRx. In a July 14 regulatory filing, Akili recorded revenue of $66,000 for the first quarter of 2022, down 44% from the prior year period. For the year 2021, the company reported revenue of $538,000, compared to $3.94 million in 2020.

The decline resulted in a larger net loss of $61 million for Akili last year.

Ned Pagliarulo contributed to this story.


Source link

]]>
Aesthetic medicine company Tian Shi Wei pockets tens of millions of RMB in Series A https://diazon.net/aesthetic-medicine-company-tian-shi-wei-pockets-tens-of-millions-of-rmb-in-series-a/ Fri, 12 Aug 2022 08:58:56 +0000 https://diazon.net/aesthetic-medicine-company-tian-shi-wei-pockets-tens-of-millions-of-rmb-in-series-a/ Dissolvable micro-needle technology has recently received a lot of industry attention and is expected to be commercialized in aesthetic medicine. Tian Shi Wei has won capital’s preference for its R&D, mass production and quality control capabilities. Dissolvable microneedle maker Tian Shi Wei (Chinese: 天时维) has raised tens of millions of RMB in a Series A […]]]>

Dissolvable micro-needle technology has recently received a lot of industry attention and is expected to be commercialized in aesthetic medicine. Tian Shi Wei has won capital’s preference for its R&D, mass production and quality control capabilities.

Dissolvable microneedle maker Tian Shi Wei (Chinese: 天时维) has raised tens of millions of RMB in a Series A funding round led by CO-WIN Ventures (Chinese: 凯风创投). Proceeds will be used to improve its team, expand the beauty and personal care business, and invest in medical device research and development.

Tian Shi Wei focuses on dissolvable micro-needle technology. Its “dissolvable microneedle eye patch”, a product of its brand ZEIT EIFE (Chinese: 俪龄之密), was launched in 2019 and was widely marketed last year. Tian Shi Wei co-founder Yongchi Zhou said the company has shipped nearly one million pairs of micro-needle eye patches, generating revenue of around 10 million yuan.

Zhou said his company’s competitive advantage lies in its mass production capacity, patents and technology. It is not difficult to manufacture dissolvable microneedles since the technology of dissolvable microneedles is largely mastered by the industry. However, achieving large-scale production and meeting changing consumer demand with its products is not easy.

Tian Shi Wei is also distinguished by the use of sodium hyaluronate (SH for short). “Currently, Tian Shi Wei can tailor the use of SH with a molecular weight of 2,000 to 40,000 according to customer needs. Most of our competitors can only use SH with a molecular weight of 10,000 or less. The compatibility of SH with different molecular weight could produce better effects on skin care.Also, the lower the molecular weight, the higher the cost.So the use of higher molecular weight SH could reduce cost effectively,” Zhou said.

Today, the company develops medical devices with dissolvable micro-needle technology. Two of its dissolvable micro-needle medical devices are expected to move into clinical trials.

Tian Shi Wei’s competitors include Youwe Biotechnology (Chinese: 优微生物科技), BIOQINGLAM (Chinese: 青澜生物), Ximei Biology (Chinese: 熙美生物).


Source link

]]>
Fig, the Food as Medicine company, calls on food manufacturers to list #EveryIngredient https://diazon.net/fig-the-food-as-medicine-company-calls-on-food-manufacturers-to-list-everyingredient/ Tue, 07 Jun 2022 13:02:00 +0000 https://diazon.net/fig-the-food-as-medicine-company-calls-on-food-manufacturers-to-list-everyingredient/ The Fig team presents a petition and pledges to finally bring greater ingredient transparency and accountability to the food industry SAN DIEGO, June 7, 2022 /PRNewswire/ — The team behind Fig, the most comprehensive food detection and sensing app available, has launched a pledge and petition calling on food manufacturers to list #EveryIngredient on their […]]]>

The Fig team presents a petition and pledges to finally bring greater ingredient transparency and accountability to the food industry

SAN DIEGO, June 7, 2022 /PRNewswire/ — The team behind Fig, the most comprehensive food detection and sensing app available, has launched a pledge and petition calling on food manufacturers to list #EveryIngredient on their product labels. The Fig team is on a mission to make everyday life easier for the approximately 100 million people in America with food allergies and other dietary restrictions. Ingredient transparency is a critical step.

Currently, more than 50% of food products on grocery store shelves contain at least one vague ingredient such as “natural flavors”, “spices” and “food starch”. To the untrained eye, an ingredient like “natural flavors” looks good. But those two words can hide thousands of ingredients, ranging from additives to animal by-products, that can cause wasted hours contacting brands, or worse, life-threatening reactions.

The long-needed #EveryIngredient movement calls on food manufacturers to tell consumers every ingredient in their products, ideally printed on the label, and at the very least when contacted. There is also a consumer petition to inspire those affected to sign, share and galvanize support around the movement and its fundamental but necessary demands.

That’s it.® and Gourmend Foods, two brands at the forefront of the ingredient transparency movement, have already shown their commitment to consumers by being the first to sign the pledge.

“We didn’t shy away from becoming one of the first food brands to sign the #EveryIngredient Pledge with Fig,” said Dr. Lior Lewensztain, Founder and CEO of That’s it.® “Consumers deserve transparency with the ingredients they put into their bodies, and we applaud Fig for demanding that food manufacturers stop hiding behind vague terms and unclear ingredient lists.”

The Fig team, a group of people with their own dietary restrictions, were inspired to create a platform to help millions of other people like them easily scan, buy and search the world of food, no matter what. be their dietary needs. In doing so, they are starting a movement to normalize discussions about dietary restrictions and bring about real change at all levels.

“We’re thrilled to help over 180,000 people like us with dietary restrictions find foods they can eat,” said Tyler Scheviak of the Fig team. “But Fig is only useful and accurate if food manufacturers are transparent. That’s why we’re asking industry to tell consumers about every ingredient in their products. There’s too much at stake to nothing less than the whole truth.”

Manufacturers can sign the pledge to www.foodisgood.com/ingredient-transparency-pledge. Consumers can sign the petition at www.everyingredient.org.

Learn more about the fig at www.foodisgood.com.

About the fig

Fig is a venture-backed technology company created by a group of people with dietary restrictions who are passionate about helping everyone live their best life through food.

Contact:
Jillian Helft
[email protected]

SOURCE Fig


Source link

]]>
Fig, the Food as Medicine company, calls on food manufacturers to list #EveryIngredient https://diazon.net/fig-the-food-as-medicine-company-calls-on-food-manufacturers-to-list-everyingredient-2/ Tue, 07 Jun 2022 07:00:00 +0000 https://diazon.net/fig-the-food-as-medicine-company-calls-on-food-manufacturers-to-list-everyingredient-2/ The Fig team presents a petition and pledges to finally bring greater ingredient transparency and accountability to the food industry SAN DIEGO, June 7, 2022 /PRNewswire/ — The team behind Fig, the most comprehensive food detection and sensing app available, has launched a pledge and petition calling on food manufacturers to list #EveryIngredient on their […]]]>

The Fig team presents a petition and pledges to finally bring greater ingredient transparency and accountability to the food industry

SAN DIEGO, June 7, 2022 /PRNewswire/ — The team behind Fig, the most comprehensive food detection and sensing app available, has launched a pledge and petition calling on food manufacturers to list #EveryIngredient on their product labels. The Fig team is on a mission to make everyday life easier for the approximately 100 million people in America with food allergies and other dietary restrictions. Ingredient transparency is a critical step.

Currently, more than 50% of food products on grocery store shelves contain at least one vague ingredient such as “natural flavors”, “spices” and “food starch”. To the untrained eye, an ingredient like “natural flavors” looks good. But those two words can hide thousands of ingredients, ranging from additives to animal by-products, that can cause wasted hours contacting brands, or worse, life-threatening reactions.

The long-needed #EveryIngredient movement calls on food manufacturers to tell consumers every ingredient in their products, ideally printed on the label, and at the very least when contacted. There is also a consumer petition to inspire those affected to sign, share and galvanize support around the movement and its fundamental but necessary demands.

That’s it.® and Gourmend Foods, two brands at the forefront of the ingredient transparency movement, have already shown their commitment to consumers by being the first to sign the pledge.

“We didn’t shy away from becoming one of the first food brands to sign the #EveryIngredient Pledge with Fig,” said Dr. Lior Lewensztain, Founder and CEO of That’s it.® “Consumers deserve transparency with the ingredients they put into their bodies, and we applaud Fig for demanding that food manufacturers stop hiding behind vague terms and unclear ingredient lists.”

The Fig team, a group of people with their own dietary restrictions, were inspired to create a platform to help millions of other people like them easily scan, buy and search the world of food, no matter what. be their dietary needs. In doing so, they are starting a movement to normalize discussions about dietary restrictions and bring about real change at all levels.

“We’re thrilled to help over 180,000 people like us with dietary restrictions find foods they can eat,” said Tyler Scheviak of the Fig team. “But Fig is only useful and accurate if food manufacturers are transparent. That’s why we’re asking industry to tell consumers about every ingredient in their products. There’s too much at stake to nothing less than the whole truth.”

Manufacturers can sign the pledge to www.foodisgood.com/ingredient-transparency-pledge. Consumers can sign the petition at www.everyingredient.org.

Learn more about the fig at www.foodisgood.com.

About the fig

Fig is a venture-backed technology company created by a group of people with dietary restrictions who are passionate about helping everyone live their best life through food.

Contact:
Jillian Helft
jheft@behrmanpr.com

Quote

Show original content:https://www.prnewswire.com/news-releases/fig-the-food-as-medicine-company-calls-on-food-manufacturers-to-list-everyingredient-301562755.html

SOURCE Fig


Source link

]]>
Fig, the food-as-medicine company, officially launches its groundbreaking mobile app, opening up a new world of dietary opportunities for people with dietary restrictions. https://diazon.net/fig-the-food-as-medicine-company-officially-launches-its-groundbreaking-mobile-app-opening-up-a-new-world-of-dietary-opportunities-for-people-with-dietary-restrictions/ Mon, 02 May 2022 13:02:00 +0000 https://diazon.net/fig-the-food-as-medicine-company-officially-launches-its-groundbreaking-mobile-app-opening-up-a-new-world-of-dietary-opportunities-for-people-with-dietary-restrictions/ The Fig app helps you find foods you CAN eat in grocery stores, no matter how complex your dietary needs. SAN DIEGO, May 2, 2022 /PRNewswire/ — The Fig app, the most comprehensive food scanning and discovery app available, officially launches today, bringing easier, more informed grocery shopping to the roughly 40-60% of Americans living […]]]>

The Fig app helps you find foods you CAN eat in grocery stores, no matter how complex your dietary needs.

SAN DIEGO, May 2, 2022 /PRNewswire/ — The Fig app, the most comprehensive food scanning and discovery app available, officially launches today, bringing easier, more informed grocery shopping to the roughly 40-60% of Americans living with dietary restrictions. It marks a milestone in Fig’s journey to empower “food as medicine” everywhere – to help everyone feel better through food.

Co-founders Max Rebarber and Andrew Hollar imagined a world where it wouldn’t take hours to find the food that meets all your needs. “For an overwhelming number of people, food is complicated, frustrating, dangerous and isolating. I can understand – from 2014 to 2017, I sought help for my severe gastrointestinal symptoms from over 20 doctors. Eventually, I turned to medical diets and for the first time in three years, I finally felt like myself again,” says the co-founder, Andrew Hollar. “However, it wasn’t easy. I needed to avoid hundreds of ingredients and spent hours searching through the grocery store. We knew there had to be a better way.

It turns out they weren’t alone in this vision. Engineers, designers, dietitians and everyday people with various dietary needs have reached out to help build the solution of their dreams, Fig.

The team released the beta version of Fig in November 2021. In five months, more than 110,000 people have used Fig without the team spending a dollar on advertising. Today, the brand is unveiling an updated visual identity and an even simpler interface, to help people easily scan, buy and search the world of food.

What makes the fig unique and popular is that you can choose from over 2,500 options to create your “fig” – whether you follow a low FODMAP diet, have a cashew nut allergy and/or you are intolerant to citric acid. You can then browse products that match your needs at over 100 grocery stores and scan ingredient labels in less than a second – for free.

More than just an app, the Fig team is building toward a world where everyone can use their Fig wherever food decisions are made – enabling personalized experiences in online grocery stores, recipe websites, restaurant menus, and more. “By simplifying complex medical diets into a simple green, yellow, and red system of education, we’ve laid the groundwork to propel accessible foods like medicine everywhere.” said co-founder Max. “We are ready to help millions of people find joy and health through food.”

Learn more at foodisgood.com or download the free app (available on iOS and Android in the US) at https://fig.app.link/

About the fig

Fig is a venture capital-backed technology company created by a group of people with dietary restrictions who are passionate about helping everyone feel better through food.

CONTACT:
Jillian Heft,
jheft@behrmanpr.com

Quote

Show original content:https://www.prnewswire.com/news-releases/fig-the-food-as-medicine-company-officially-launches-its-revolutionary-mobile-app-opening-a-new-world-of-food- opportunity-for-those-with-dietary-restrictions-301537102.html

SOURCE Fig


Source link

]]>
Shares of traditional Chinese medicine company rise following Covid outbreak https://diazon.net/shares-of-traditional-chinese-medicine-company-rise-following-covid-outbreak/ Tue, 05 Apr 2022 07:00:00 +0000 https://diazon.net/shares-of-traditional-chinese-medicine-company-rise-following-covid-outbreak/ The stake held by the founding family of one of China’s largest traditional medicine groups has soared in value to $4.5 billion after the country’s latest Covid-19 outbreaks sparked renewed interest for his coronavirus treatment. Despite the United States explicitly warning against the company’s drugs, shares of billionaire Wu Yiling’s pharmaceutical company, Shijiazhuang Yiling Pharmaceutical, […]]]>

The stake held by the founding family of one of China’s largest traditional medicine groups has soared in value to $4.5 billion after the country’s latest Covid-19 outbreaks sparked renewed interest for his coronavirus treatment.

Despite the United States explicitly warning against the company’s drugs, shares of billionaire Wu Yiling’s pharmaceutical company, Shijiazhuang Yiling Pharmaceutical, have jumped more than 60% since late December. The latest rally added to the stock’s 160% gain at the start of 2020 after Beijing endorsed its Covid treatment.

Shijiazhuang Yiling’s share price hovered around Rmb8 ($1.26) before the pandemic, but recently hit record highs after the drug was promoted in Hong Kong, closing last week at Rmb31.5. . The rally pushed the value of the owner family’s nearly 55% stake in the company, listed on the Shenzhen Stock Exchange, to around Rmb28.8 billion.

Wu is famous in China for developing a remedy from millipede, scorpion, leech and cicada to treat cardiovascular disease. His company sells a distinct herbal remedy called Lianhua Qingwen, with ingredients such as honeysuckle, licorice root, apricot seed and forsythia, as a treatment for coronavirus. Wu’s company remedy has been endorsed by both Zhong Nanshan, an expert advising the Chinese government on the coronavirus, and Hong Kong leader Carrie Lam.

Hong Kong has been reeling from its biggest Covid outbreak of the pandemic as cases also rise in China, forcing financial hub Shanghai and other cities into lockdown.

Beijing has been actively promoting traditional Chinese medicine on the world stage in recent years, and state media have trumpeted Shijiazhuang Yiling’s success in gaining regulatory approval in African and Middle Eastern countries.

But the US Food and Drug Administration, as well as authorities in Singapore and Australia, warned there was no evidence Lianhua Qingwen had any effect on the virus and cautioned against its use.

The FDA said claims that Lianhua Qingwen could prevent or treat Covid were “not supported by competent and reliable scientific evidence”, while Singapore authorities said in November that there was “no evidence scientific” to show that it can be used to prevent or treat Covid.

The dramatic rise in the company’s stock began after Lianhua Qingwen was recommended in Beijing’s official treatment protocols for the coronavirus in March 2020.

Wu holds a 31.5% stake in the company, while his son and daughter Wu Xiangjun and Wu Rui collectively own 23%, according to the company’s latest quarterly report.

From mid-2020 to late 2021, Shijiazhuang Yiling’s share price was volatile but slid lower as China and Hong Kong appeared to have successfully contained the virus.

A version of the drug that was distributed in mainland China was not initially approved in Hong Kong, and local health officials raided pharmacies selling it as recently as February.

But pro-Beijing lawmakers lobbied the Hong Kong government in March, at the height of the territory’s Omicron wave, to offer exemptions to drug batches. Mainland businesses have donated hundreds of thousands of packs to the city.

Pharmacists working in Hong Kong have said they fear the spread of counterfeit versions of the remedy.

“The question is whether there will be counterfeit versions being sold in Hong Kong and whether citizens will come to recognize them,” said pharmacist Philip Chan. “Without proper registration, drugs could become a public health problem.”


Source link

]]>
Isis Pharmaceuticals, Medicine Company – corporate philosophy https://diazon.net/isis-pharmaceuticals-medicine-company-corporate-philosophy/ Wed, 02 Mar 2022 09:09:49 +0000 https://diazon.net/isis-pharmaceuticals-medicine-company-corporate-philosophy/ Atherosclerosis Drugs Market report focused on the comprehensive analysis of the current and future outlook of the Atherosclerosis Drugs industry. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during […]]]>

Atherosclerosis Drugs Market report focused on the comprehensive analysis of the current and future outlook of the Atherosclerosis Drugs industry. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements of the Atherosclerosis Drugs Market has been performed to calculate the growth rates of each segment and sub-segments.

Get a sample copy (including full TOC, charts, and tables) of this report:

https://www.a2zmarketresearch.com/sample-request/327794

Leading companies in this report include: Isis Pharmaceuticals, Medicine Company, Johnson and Johnson, F Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline Plc, Sanofi, Merck & Co, Cardium Therapeutics, Anthera Pharmaceuticals, Novartis AG.

Various factors are responsible for the growth trajectory of the market, which are studied extensively in the report. In addition, the report lists down the restraints that threaten the global Atherosclerosis Drugs market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics and forecasts for various segments and sub-segments considering macro and micro environmental factors. It also assesses the bargaining power of suppliers and buyers, the threat of new entrants and product substitutes, and the degree of competition prevailing in the market.

The influence of the latest government directives is also analyzed in detail in the report. It studies the Atherosclerosis Drugs market’s trajectory between forecast periods. The cost analysis of Global Atherosclerosis Drugs Market has been performed while considering manufacturing expense, labor cost, and raw materials along with their market concentration rate, vendors and the price trend.

Global Atherosclerosis Drugs Market Segmentation:

Market Segmentation: By Type

Drugs, Surgery Drugs

Market Segmentation: By Application

Hospitals, Clinics, Others

The research provides answers to the following key questions:

  • What is the projected market size of the Atherosclerosis Drugs market by 2029?
  • What will be the normal share of the whole industry for the coming years?
  • What is the significant development of components and restraints in the Global Atherosclerosis Drugs Market across different geographies?
  • Who are the top sellers expected to lead the market for the assessment period 2022 to 2029?
  • What are the moving and emerging advancements expected to influence the advancement of the Global Atherosclerosis Drugs Market?
  • What are the development techniques received by the important sellers of the market to stay on the lookout?

Get an exclusive discount on this report:

https://www.a2zmarketresearch.com/discount/327794

Regions Covered in the Global Atherosclerosis Drugs Market Report 2022:
The Middle East and Africa (GCC countries and Egypt)
North America (United States, Mexico and Canada)
South America (Brazil, etc)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Reasons to buy this report:

  • It offers an analysis of the evolution of the competitive scenario.
  • To make informed decisions in businesses, it offers analytical data with strategic planning methodologies.
  • The researchers shed light on market dynamics, such as drivers, restraints, trends, and opportunities.
  • It offers regional analysis of Atherosclerosis Drugs Market along with business profiles of several stakeholders.
  • It offers a seven-year assessment of the atherosclerosis drug market.
  • It helps in understanding the major key product segments.
  • It offers massive data about the trending factors that will influence the progress of the Atherosclerosis Drugs Market.

Contents

Global Atherosclerosis Drugs Market Research Report 2022-2029

Chapter 1 Atherosclerosis Drugs Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 – Global Atherosclerosis Drugs Market Forecast

Buy an exclusive report on:

https://www.a2zmarketresearch.com/checkout

If you have any special requirements, please let us know and we will offer you the report you want. you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About A2Z Market Research:

The A2Z Market Research Library provides market research syndication reports from around the world. Buy-ready syndication Market research will help you find the most relevant business intelligence.

Our research analyst provides business insights and market research reports for large and small businesses.

The company helps its clients to develop business policies and grow in this market. A2Z Market Research is interested not only in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F&B , media, etc., but also your company data, country profiles, trends, information. and analysis on the sector that interests you.

Contact us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147


Source link

]]>
Genexa, the First and Only Clean Medicine Company, Appoints Chief Marketing Officer | Your money https://diazon.net/genexa-the-first-and-only-clean-medicine-company-appoints-chief-marketing-officer-your-money/ Thu, 17 Feb 2022 14:02:26 +0000 https://diazon.net/genexa-the-first-and-only-clean-medicine-company-appoints-chief-marketing-officer-your-money/ ATLANTA–(BUSINESS WIRE)–February 17, 2022– Genexamaker of the world’s first clean medicines – made with the same effective active ingredients as conventional brands but without any of the artificial fillers – named Emily Culp as the company’s new Chief Marketing Officer (CMO). Culp will lead all branding, marketing and e-commerce strategy for Genexa, bringing with her […]]]>

ATLANTA–(BUSINESS WIRE)–February 17, 2022–

Genexamaker of the world’s first clean medicines – made with the same effective active ingredients as conventional brands but without any of the artificial fillers – named Emily Culp as the company’s new Chief Marketing Officer (CMO). Culp will lead all branding, marketing and e-commerce strategy for Genexa, bringing with her more than two decades of marketing and e-commerce experience and a proven track record of accelerating growth by creating consumer-centric brands across channels and geographies, driving business transformation and introducing innovative new products.

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220217005233/en/

Emily Culp (Photo: Business Wire)

Culp joins Genexa at an exciting time of strong growth. In 2021, Genexa has expanded its retail footprint to 45,000 stores nationwide, including key retail partners such as Walmart, Target, Rite Aid, CVS, Whole Foods as well as online at Genexa.com and Amazon. The company also launched its first national broadcast marketing campaign and closed a highly successful and oversubscribed $60 million Series A that brought together some of the world’s most highly regarded consumer product investors. Hollywood’s top wellness advocates also took part in Series A, the biggest ever for a consumer pharmaceutical company. Famous investors passionate about the clean medicine movement include Gwyneth Paltrow, Chris Pratt, Katherine Schwarzenegger, Donald Glover, Lily Aldridge, Jennifer Meyer, Regina Hall, Sanaa Lathan, Don Cheadle, Bridgid Coulter, Lana Parrilla, Patrick Schwarzenegger, Tony Kanal, Zoey Deutch and Nikki Reed.

“We are very excited about the future of clean medicine, and Emily couldn’t be a better leader to help accelerate Genexa’s growth and embed our brand and our core mission – people first – in the hearts and minds of our consumers,” noted Co-founder and CEO of Genexa david johnson. “We are committed to giving everyone access to real choices and Emily’s passion and experience for mission-driven businesses will help shape our voice and brand with customers.”

“Genexa is doing something that I have never seen before in my decades of experience in over-the-counter drugs,” adds Genexa’s President Brian Perkins. “Inspired by putting people above all else, Genexa is driving innovation by challenging the way over-the-counter medicines are formulated, bringing safe, clean medicines to market in a way never before seen. possible. Emily’s passion and experience with mission-driven companies like ours will help shape our voice and brand with customers. »

Covering all traditional over-the-counter treatment categories, including colds and flu, pain relievers, digestion and allergies for infants, children and adults, Genexa’s medications have the same active ingredients as the leaders in category but, for the very first time, are made without any artificial inactive ingredients. including the plethora of artificial colors, talc, sorbitol, high fructose corn syrup, propylene glycol, titanium dioxide, and common allergens like gluten and lactose.

“I am honored and delighted to join Genexa. I deeply believe in the vision that Max and David have set forth – to finally give people the real choice to use medicines that are both effective and clean, medicines made by people who truly care about you and your family,” said Emily Culp, CMO of Genexa. “Years of development with leading doctors and experts means that there is finally effective medicine available without artificial colors, flavors and common allergens while retaining all the active ingredients you really need. To me, that means that better health options are finally available to everyone, and they’re made by a company that puts people first in every way.

Most recently, Emily was CEO of Cover FX, a clean beauty brand with a global presence across all channels. She led the transformation of the company by pivoting the business model to be more consumer-centric, global and DTC-focused and introducing new patent-pending products. Her leadership and vision have allowed Cover FX to maintain its position as a pioneer in the clean beauty category while adapting to changes within the industry.

Prior to joining Cover FX, Emily was Global CMO at Keds, where she was responsible for the strategic development and creative execution of Keds’ global marketing initiatives including retail development, omnichannel marketing, e-commerce, public relations, content development and product collaborations. Emily has also held global omnichannel marketing and retail transformation roles at Rebecca Minkoff, Clinique and Unilever. She was responsible for launching programs such as the “store of the future” at Rebecca Minkoff, negotiating the partnership between Unilever and Amazon, launching Clinique’s social media presence and expanding the DTC business. worldwide. She began her career in various positions with agencies such as Ogilvy & Mather, Arnold and Digitas.

Emily was recognized in Forbes as one of the most influential CMOs in the world, Business Intern on the list of the 50 most innovative CMOs in the world and on the Adweek 50 list. She frequently lectures at Columbia University and has spoken at many high-profile industry events, including boutique.org, NRF, Google Retail Summit and SXSW. Culp holds an MBA from Columbia University and a BA from Wake Forest University.

All of Genexa’s products are manufactured in accordance with relevant FDA guidelines and are project verified non-GMO and gluten-free. Many are also certified organic and vegan. As a Certified B-Corporation, Genexa is committed to using business as a force for good, adhering to rigorous standards of social and environmental performance, accountability and transparency.

For more information, visit Genexa.com.

ABOUT GENEXA

Founded by two fathers on a mission to revolutionize the medicine aisle, Genexa makes medicine with the same active ingredients people need, but without the artificial ingredients they don’t. We believe people deserve choices. That’s why our business is built on a commitment to putting people above everything else. All of our products are made to the highest medical standards with no artificial colors, common allergens or unnecessary inactive ingredients. It’s real medicine, made clean. Find out how we put people above all else, in everything we do, at Genexa.com.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220217005233/en/

CONTACT: SUPERJUICE

Alison Blue

ablue@superjuiceco.com

KEYWORD: UNITED STATES NORTH AMERICA GEORGIA

INDUSTRY KEYWORD: PHARMACEUTICALS ALTERNATIVE MEDICINE HEALTH CARE SPECIALTY ONLINE RETAILER RETAIL OTHER HEALTH

SOURCE: Genexa

Copyright BusinessWire 2022.

PUBLISHED: 02/17/2022 09:00 AM / DISK: 02/17/2022 09:02 AM

http://www.businesswire.com/news/home/20220217005233/en


Jury rejects Sarah Palin's lawsuit against the New York Times


Source link

]]>